Literature DB >> 11683578

Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice.

Y Tanaka1, S Koido, D Chen, S J Gendler, D Kufe, J Gong.   

Abstract

Fusions of autologous tumor cells with allogeneic dendritic cells (DC) represent an approach for the induction of antitumor immunity. In the present studies, we investigated the antitumor effects of vaccinating MUC1-transgenic (MUC1.Tg) mice with MC38/MUC1 carcinoma cells fused to allogeneic DC from BALB/c mice (allo-DC, H-2(d)) or syngeneic DC from C57BL/6 mice (syn-DC, H-2(b)). Both allo and syn fusion cells (FC/MUC1) expressed MHC class II, costimulatory molecules, and the MUC1 antigen. Allo-FC/MUC1 exhibited dual expression of MHC class I haplotypes (H-2(d)/H-2(b))and MUC1 antigen. By contrast, only H-2(b) and MUC1 antigen were expressed by syn-FC/MUC1. CTLs from MUC1.Tg mice immunized with allo- or syn-FC/MUC1 fusion cells lysed MC38/MUC1 targets. Moreover, immunization with allo- or syn-FC/MUC1 was effective in eliminating established MUC1-positive pulmonary metastases in MUC1.Tg mice. These results indicate that immunization of MUC1.Tg mice with syn- or allo-FC/MUC1 is effective in reversing immunologic unresponsiveness to MUC1 antigen and inducing immunity against MUC1-positive tumors. The findings in the present study have broader clinical implications for fusion cell vaccines. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683578     DOI: 10.1006/clim.2001.5112

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  13 in total

1.  Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo.

Authors:  Jin-Kun Zhang; Jun Li; Juan Zhang; Hai-Bin Chen; Su-Biao Chen
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

Review 2.  Cancer vaccine by fusions of dendritic and cancer cells.

Authors:  Shigeo Koido; Eiichi Hara; Sadamu Homma; Yoshihisa Namiki; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Clin Dev Immunol       Date:  2010-02-18

Review 3.  Whole tumor antigen vaccines.

Authors:  Cheryl Lai-Lai Chiang; Fabian Benencia; George Coukos
Journal:  Semin Immunol       Date:  2010-03-30       Impact factor: 11.130

4.  Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells.

Authors:  Shigeo Koido; Yasuhiro Tanaka; Hisao Tajiri; Jianlin Gong
Journal:  Vaccine       Date:  2007-01-03       Impact factor: 3.641

5.  Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect.

Authors:  Dodie S Pouniotis; Owen Proudfoot; Violeta Bogdanoska; Vasso Apostolopoulos; Theodora Fifis; Magdalena Plebanski
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

6.  Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells.

Authors:  Shigeo Koido; Sadamu Homma; Eiichi Hara; Yoshihisa Namiki; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  J Biomed Biotechnol       Date:  2010-04-07

Review 7.  Promising novel immunotherapies and combinations for prostate cancer.

Authors:  Philip M Arlen; Mahsa Mohebtash; Ravi A Madan; James L Gulley
Journal:  Future Oncol       Date:  2009-03       Impact factor: 3.404

8.  Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses.

Authors:  S Homma; Y Sagawa; M Ito; T Ohno; G Toda
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

9.  Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy.

Authors:  Alison Merrick; Rosa Maria Diaz; Dearbhaile O'Donnell; Peter Selby; Richard Vile; Alan Melcher
Journal:  Cancer Immunol Immunother       Date:  2007-12-04       Impact factor: 6.968

Review 10.  Current perspectives in prostate cancer vaccines.

Authors:  Philip M Arlen; James L Gulley
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.